Rates of blinatumomab-related toxicities in pediatric trials
| Study . | CRS . | Neurologic events . | Other notable toxicities . | ||||
|---|---|---|---|---|---|---|---|
| Encephalopathy . | Seizure . | ||||||
| Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | ||
| Von Stackelberg et al5 | 11% | 6% | Grade 3 neurologic events: 4% | ||||
| Locatelli et al6,7 | 16.4% | 1.8% | Grade 3 neurologic events: 3.6% | ||||
| Locatelli et al8,9 | 3.7%% | 0% | 1.9% | — | 3.7% | Grade 4: 1.9% | — |
| Brown et al10 | 22% | 1% | 15% | — | 5% | 1% | — |
| Hogan et al11 | 15% | 2% | 29% | — | 6% | 2% | — |
| Van der Sluis et al12 | 3.3% | — | No neurologic events reported | — | |||
| Gupta et al13 | — | 0.2% | — | 0.1% | — | 0.8% | Grade ≥3 sepsis and catheter-related infections during overall protocol therapy: Average risk: with blina 14.8% vs 5.1% chemotherapy only∗ Higher risk: 20.9% with blina vs 17% with chemotherapy only |
| Study . | CRS . | Neurologic events . | Other notable toxicities . | ||||
|---|---|---|---|---|---|---|---|
| Encephalopathy . | Seizure . | ||||||
| Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | ||
| Von Stackelberg et al5 | 11% | 6% | Grade 3 neurologic events: 4% | ||||
| Locatelli et al6,7 | 16.4% | 1.8% | Grade 3 neurologic events: 3.6% | ||||
| Locatelli et al8,9 | 3.7%% | 0% | 1.9% | — | 3.7% | Grade 4: 1.9% | — |
| Brown et al10 | 22% | 1% | 15% | — | 5% | 1% | — |
| Hogan et al11 | 15% | 2% | 29% | — | 6% | 2% | — |
| Van der Sluis et al12 | 3.3% | — | No neurologic events reported | — | |||
| Gupta et al13 | — | 0.2% | — | 0.1% | — | 0.8% | Grade ≥3 sepsis and catheter-related infections during overall protocol therapy: Average risk: with blina 14.8% vs 5.1% chemotherapy only∗ Higher risk: 20.9% with blina vs 17% with chemotherapy only |
blina, blinatumomab.
Statistically significant compared with patients randomized to chemotherapy alone.